Inuvair (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Beclometasone dipropionate activates glucocorticoid receptors, suppressing inflammatory gene expression and decreasing airway swelling. Formoterol fumarate selectively stimulates β2‑adrenergic receptors, raising cyclic AMP levels in airway smooth muscle, which produces prolonged bronchodilation. Together they provide anti‑inflammatory and bronchodilator actions essential for disease control.

The dosage of Inuvair is individualized. A qualified prescriber determines the appropriate number of inhalations per day based on the patient’s age, disease severity, and response to therapy. Patients should follow the specific instructions provided by their healthcare professional.

Safety data for Inuvair in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual risk factors and consider alternative treatments when appropriate.

To order Inuvair, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and assistance with import documentation.

Inuvair combines beclometasone, a potent corticosteroid, with formoterol, a rapid‑onset long‑acting β2‑agonist. Compared with other combinations such as budesonide/formoterol, Inuvair offers a similar dual mechanism but may differ in potency, particle size, and device design. Choice of inhaler depends on patient preference, inhalation technique, and clinical response.

Store Inuvair at ambient temperature, below 25 °C, in its original packaging. Keep the inhaler away from moisture, direct sunlight, and heat sources. Do not expose the device to freezing temperatures, and ensure the mouthpiece remains clean to maintain dose accuracy.

Inuvair is delivered via inhalation. The patient should shake the inhaler (if required), exhale fully, place the mouthpiece in the mouth, and inhale slowly and deeply while actuating the device. Holding the breath for about 10 seconds maximises drug deposition. Using a spacer can further reduce oropharyngeal deposition.

Serious risks include paradoxical bronchospasm, adrenal suppression with prolonged high‑dose use, severe hypersensitivity reactions such as anaphylaxis, and cardiac effects like tachycardia or arrhythmias. Patients should seek immediate medical attention if they experience sudden worsening of breathing, rash, swelling, or palpitations.

Inuvair is contraindicated in individuals with a known hypersensitivity to beclometasone, formoterol, or any excipients in the inhaler. It should also be avoided in patients who have experienced a severe allergic reaction to other inhaled corticosteroids or long‑acting β2‑agonists. Clinicians must assess each patient’s medical history before prescribing.